Haemonetics (HAE) 10-Q 30 Oct 13 2014 Q2 Quarterly report Financial data

DOCUMENT_AND_ENTITY_INFORMATIO

DOCUMENT AND ENTITY INFORMATION	6 Months Ended
	Sep. 28, 2013
Document And Entity Information [Abstract]
Entity Registrant Name	HAEMONETICS CORP
Entity Central Index Key	313143
Current Fiscal Year End Date	-26
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	28-Sep-13
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q2
Amendment Flag	FALSE
Entity Common Stock, Shares Outstanding	51,528,003

CONSOLIDATED_STATEMENTS_OF_INC

CONSOLIDATED STATEMENTS OF INCOME (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012
Income Statement [Abstract]
Net revenues	$235,755	$218,178	$455,297	$394,653
Cost of goods sold	115,871	116,416	224,002	202,778
Gross profit	119,884	101,762	231,295	191,875
Operating expenses:
Research and development	14,946	10,827	26,155	20,235
Selling, general and administrative	81,508	81,034	188,318	148,659
Total operating expenses	96,454	91,861	214,473	168,894
Operating income	23,430	9,901	16,822	22,981
Interest and other expense, net	-2,542	-1,311	-5,183	-975
Income before provision for income taxes	20,888	8,590	11,639	22,006
Income tax expense	4,340	2,043	2,965	5,671
Net income	16,548	6,547	8,674	16,335
Net income per share - basic (in dollars per share)	$0.32	$0.13	$0.17	$0.32
Net income per share - diluted (in dollars per share)	$0.32	$0.13	$0.17	$0.31
Weighted average shares outstanding
Basic (in shares)	51,492	51,420	51,360	51,192
Diluted (in shares)	52,361	52,314	52,200	52,088
Comprehensive income	$15,308	$5,863	$7,174	$11,781

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 28, 2013	Mar. 30, 2013
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$159,148	$179,120
Accounts receivable, less allowance of $1,740 at September 28, 2013 and $1,727 at March 30, 2013	162,084	170,111
Inventories, net	205,251	183,784
Deferred tax asset, net	14,454	13,782
Prepaid expenses and other current assets	51,144	50,213
Total current assets	592,081	597,010
Property, plant and equipment:
Total property, plant and equipment	662,735	632,720
Less: accumulated depreciation	-404,468	-375,767
Net property, plant and equipment	258,267	256,953
Other assets:
Intangible assets, less amortization of $86,608 at September 28, 2013 and $72,393 at March 30, 2013	277,065	264,388
Goodwill	341,673	330,474
Deferred tax asset, long term	1,751	1,751
Other long-term assets	13,409	11,341
Total other assets	633,898	607,954
Total assets	1,484,246	1,461,917
Current liabilities:
Notes payable and current maturities of long-term debt	43,687	23,150
Accounts payable	45,380	49,893
Accrued payroll and related costs	44,101	45,697
Accrued income taxes	4,403	4,053
Other liabilities	60,617	57,351
Total current liabilities	198,188	180,144
Long-term debt, net of current maturities	420,711	456,944
Long-term deferred tax liability	29,265	29,552
Other long-term liabilities	39,609	26,095
Stockholders’ equity:
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 51,528,003 shares at September 28, 2013 and 51,031,563 shares at March 30, 2013	515	510
Additional paid-in capital	385,153	365,040
Retained earnings	406,873	398,199
Accumulated other comprehensive income	3,932	5,433
Total stockholders’ equity	796,473	769,182
Total liabilities and stockholders’ equity	$1,484,246	$1,461,917

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) (USD $)	Sep. 28, 2013	Mar. 30, 2013
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$1,740	$1,727
Intangible assets, amortization	$86,608	$72,393
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	51,528,003	51,031,563
Common stock, shares outstanding (in shares)	51,528,003	51,031,563

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012
Cash Flows from Operating Activities:
Net income	$8,674	$16,335
Non-cash items:
Depreciation and amortization	38,256	28,610
Amortization of financing costs	815	0
Stock compensation expense	6,416	5,014
Purchase of in-process R&D	3,569	0
Loss on sale of property, plant and equipment	265	218
Unrealized loss from hedging activities	2,266	166
Interest expense on contingent consideration	310	0
Asset write-down	1,675	0
Change in operating assets and liabilities:
Decrease/(increase) in accounts receivable, net	8,689	-22,686
Increase in inventories	-19,338	-3,448
Increase in prepaid income taxes	-1,459	-2,197
Decrease/(increase) in other assets and other liabilities	5,067	-4,337
Tax benefit of exercise of stock options	1,338	2,488
(Increase)/decrease in accounts payable and accrued expenses	-13,781	13,404
Net cash provided by operating activities	42,762	33,567
Cash Flows from Investing Activities:
Capital expenditures on property, plant and equipment	-28,202	-34,432
Proceeds from sale of property, plant and equipment	642	355
Acquisition of Hemerus	0	-535,144
Acquisition of Hemerus	-23,124	-1,000
Other acquisitions and investments	-8,707	0
Net cash used in investing activities	-59,391	-570,221
Cash Flows from Financing Activities:
Payments on long-term real estate mortgage	-472	-434
Net increase in short-term loans	4,240	3,217
Term loan borrowing	0	475,000
Repayment of term loan borrowings	-20,000	0
Debt issuance costs	0	-5,462
Proceeds from employee stock purchase plan	2,666	2,105
Proceeds from exercise of stock options	8,117	23,649
Excess tax benefit on exercise of stock options	1,581	2,079
Share repurchase	0	-5,342
Net cash (used in)/provided by financing activities	-3,868	494,812
Effect of exchange rates on cash and cash equivalents	525	32
Net Decrease in Cash and Cash Equivalents	-19,972	-41,810
Cash and Cash Equivalents at Beginning of Period		228,861
Cash and Cash Equivalents at End of Period	159,148	187,051
Non-cash Investing and Financing Activities:
Transfers from inventory to fixed assets for placements of Haemonetics equipment	6,034	11,167
Supplemental Disclosures of Cash Flow Information:
Interest paid	4,722	1,688
Income taxes paid	$3,666	$7,338

BASIS_OF_PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Sep. 28, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION
	Our accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of our management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. All intercompany transactions have been eliminated. Operating results for the six months ended are not necessarily indicative of the results that may be expected for the full fiscal year ending March 29, 2014, or any other interim period. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements and footnotes included in our annual report on Form 10-K for the fiscal year ended March 30, 2013.
	We consider events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. We had no significant subsequent events.
	Our fiscal year ends on the Saturday closest to the last day of March. Fiscal years 2014 and 2013 include 52 weeks with each quarter having 13 weeks.

RECENT_ACCOUNTING_PRONOUNCEMEN

RECENT ACCOUNTING PRONOUNCEMENTS	6 Months Ended
	Sep. 28, 2013
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS
	New pronouncements issued but not effective until after September 28, 2013 are not expected to have a material impact on financial position, results of operation or liquidity.
	Standards Implemented
	In July 2013 the Financial Accounting Standards Board ("FASB") issued ASU 2013-10 Derivatives and Hedging (Topic 815): Inclusion of the Fed Funds Effective Swap Rate (or Overnight Index Swap Rate) as a Benchmark Interest Rate for Hedge Accounting Purposes. ASU 2013-10 amends ASC 815 to include the Fed Funds Effective Swap Rate (or Overnight Index Swap Rate) as a benchmark interest rate for hedge accounting purposes in addition to UST and LIBOR. The amendments also remove the restriction on using different benchmark rates for similar hedges. The amendments are effective prospectively for qualifying new or redesignated hedging relationships entered into on or after July 17, 2013. We have evaluated the amendments and conclude that these do not impact our financial statements as we have not entered into transactions with Fed Funds Effective Swap Rate.
	In February 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2013-02, Comprehensive Income: Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income ("ASU 2013-02"). ASU 2013-02 requires an entity to provide information about amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present, either on the face of the financial statements or in a single note; any significant amount reclassified out of accumulated other comprehensive income in its entirety in the period, and the income statement line item affected by the reclassification. For other amounts that are not required under U.S. GAAP to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures required under U.S. GAAP that provide additional detail about those amounts. We adopted this guidance during the three months ended June 29, 2013.

ACQUISITIONS

ACQUISITIONS	6 Months Ended
	Sep. 28, 2013
Business Combinations [Abstract]
ACQUISITIONS	ACQUISITIONS
	Hemerus Acquisition
	On April 30, 2013 we completed the acquisition of certain assets of Hemerus LLC ("Hemerus"), a Minnesota based company that develops innovative technologies for the collection of whole blood and processing and storage of blood components. Hemerus has received U.S Food and Drug Administration (FDA) approval for SOLX® whole blood collection system for eight hour storage of whole blood prior to processing. Hemerus previously received Conformité Européenne or CE Mark in the European Union to market SOLX as the world's first 56-day red blood cell storage solution. We paid $24.1 million cash and will pay an additional $3.0 million upon a further FDA approval of the SOLX solution for 24 hour storage of whole blood prior to processing. We will also pay up to $14.0 million based on future sales of SOLX-based products through fiscal 2024.
	We acquired Hemerus to complement the portfolio of whole blood collection, filtration and processing product lines we recently acquired and to bring greater efficiency and productivity to whole blood collection and processing. Hemerus manufactures and sells manual blood collection systems and filters and has operations in North America. Expected revenue from the sale of SOLX will be reported within the blood center disposables product line.
	The assets acquired from Hemerus were recorded at fair value at the date of acquisition. The allocation of purchase price is preliminary, and subject to change based primarily on finalization of the valuation of the acquired intangible assets.
	The preliminary purchase price allocation is as follows:
	Asset class	Amounts Recognized as of September 28, 2013
	(In thousands)
	Intangible assets	$	20,400
	Goodwill	10,324
	Fair value of net assets acquired	$	30,724
	The preliminary fair value of the acquired assets are reflected in the consolidated balance sheets.
	The $20.4 million of acquired intangible assets was allocated to developed technology. Goodwill represents the excess of the purchase price over the fair value of the net assets. Goodwill of $10.3 million primarily represents future economic benefits expected to arise from the work force and synergies expected to be gained from the integration of SOLX into our whole blood products. Prior to the acquisition, we had not conducted any business with Hemerus.
	Contingent consideration
	As described above, we will pay the sellers of Hemerus assets up to $14.0 million based on future sales of SOLX. We recognized a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We will revalue this liability each reporting period and record necessary changes in the fair value in our consolidated statements of operations. As of September 28, 2013, the maximum amount of future contingent consideration (undiscounted) that we could be required to pay related to future SOLX sales is $14.0 million. Additionally we will pay $3.0 million upon FDA approval of the SOLX solution for 24 hour storage of whole blood prior to processing.
	Contingent consideration liabilities are measured at fair value using projected revenues, discount rates, probabilities of payment and projected payment dates. This Level 3 fair value measurement was performed using a probability-weighted discounted cash flow over a ten year period.
	Increases or decreases in the fair value of our contingent consideration liability can result from changes in discount periods and rates, as well as changes in the timing and amount of revenue estimates or likelihood of earning revenue. Projected revenues are based on our most recent internal operational budgets and long-range strategic plans.

EARNINGS_PER_SHARE_EPS

EARNINGS PER SHARE ("EPS")	6 Months Ended
	Sep. 28, 2013
Earnings Per Share [Abstract]
EARNINGS PER SHARE (EPS)	EARNINGS PER SHARE (“EPS”)
	The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations. Basic EPS is computed by dividing net income by weighted average shares outstanding. Diluted EPS includes the effect of potentially dilutive common shares. The common stock weighted average number of shares has been retroactively adjusted for the stock split that occurred on November 30, 2012.
		Three Months Ended
	(In thousands, except per share amounts)	September 28,		September 29,
		2013		2012
	Basic EPS
	Net income	$	16,548	$	6,547
	Weighted average shares	51,492		51,420
	Basic income per share	$	0.32	$	0.13
	Diluted EPS
	Net income	$	16,548	$	6,547
	Basic weighted average shares	51,492		51,420
	Net effect of common stock equivalents	869		894
	Diluted weighted average shares	52,361		52,314
	Diluted income per share	$	0.32	$	0.13
		Six Months Ended
	(In thousands, except per share amounts)	September 28, 2013		September 29, 2012
	Basic EPS
	Net income	$	8,674	$	16,335
	Weighted average shares	51,360		51,192
	Basic income per share	$	0.17	$	0.32
	Diluted EPS
	Net income	$	8,674	$	16,335
	Basic weighted average shares	51,360		51,192
	Net effect of common stock equivalents	840		896
	Diluted weighted average shares	52,200		52,088
	Diluted income per share	$	0.17	$	0.31
	Weighted average shares outstanding, assuming dilution, excludes the impact of a negligible number and 0.8 million shares for the three and six months ended September 28, 2013 respectively and 0.1 million and 0.4 million for the three and six months ended September 29, 2012, respectively, because these securities were anti-dilutive during the noted periods.

STOCKBASED_COMPENSATION

STOCK-BASED COMPENSATION	6 Months Ended
	Sep. 28, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION
	Stock-based compensation expense of $6.4 million and $5.0 million were recognized for the six months ended September 28, 2013 and September 29, 2012, respectively. The related income tax benefit recognized was $2.1 million and $1.6 million for the six months ended September 28, 2013 and September 29, 2012, respectively.
	During the three months ended September 28, 2013 we granted a “target” number of 300,000 market stock units to 13 senior executives.  Holders of market stock units are eligible to receive a share of Haemonetics’ stock for each market stock unit based on the performance of the stock through March 31, 2017.  If our stock is below a minimum threshold price of $50 per share during the relevant measurement period, the holders receive no market share units. If the stock achieves certain price levels, the holders are eligible to receive up to three times the “target” amount of market share units. As a result, we may issue up to 900,000 shares at a stock price of $85 per share or higher in connection with these grants. We determined the fair value of the target number of market stock units was $37.42 utilizing a Monte Carlo simulation model based on an expected term of 3.7 years, a risk free rate of 0.9%, volatility of 20% and no dividends.  The fair value of these awards totaling $11.2 million will be expensed evenly over the 3.7 year period through the cliff-vesting date of March 31, 2017.
	The weighted average fair value for our options granted was $10.98 and $9.01 for the six months ended September 28, 2013 and September 29, 2012, respectively. The assumptions utilized for estimating the fair value of option grants during the periods presented are as follows:
		Six Months Ended
		September 28,		September 29,
		2013		2012
	Stock Options Black-Scholes assumptions (weighted average):
	Volatility	25.49	%	27.18	%
	Expected life (years)	5		5
	Risk-free interest rate	1.4	%	0.62	%
	Dividend yield	—	%	—	%
	During the six months ended September 29, 2012 and September 29, 2012, there were 81,465 and 84,514 shares, respectively, purchased under the Employee Stock Purchase Plan at an average price of $32.73 and $24.92 per share, respectively.

PRODUCT_WARRANTIES

PRODUCT WARRANTIES	6 Months Ended
	Sep. 28, 2013
Product Warranties Disclosures [Abstract]
PRODUCT WARRANTIES	PRODUCT WARRANTIES
	We generally provide a warranty on parts and labor for one year after the sale and installation of each device. We also warrant our disposables products through their use or expiration. We estimate our potential warranty expense based on our historical warranty experience, and we periodically assess the adequacy of our warranty accrual and make adjustments as necessary.
		Six Months Ended
	(In thousands)	September 28,			September 29,
		2013			2012
	Warranty accrual as of the beginning of the period	$	673		$	796
	Warranty provision	775			806
	Warranty spending	(723		)	(886		)
	Warranty accrual as of the end of the period	$	725		$	716

INVENTORIES

INVENTORIES	6 Months Ended
	Sep. 28, 2013
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES
	Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined on the first-in, first-out method.
	(In thousands)	September 28, 2013		30-Mar-13
	Raw materials	$	77,348	$	70,716
	Work-in-process	7,292		7,829
	Finished goods	120,611		105,239
		$	205,251	$	183,784

DERIVATIVES_AND_FAIR_VALUE_MEA

DERIVATIVES AND FAIR VALUE MEASUREMENTS	6 Months Ended
	Sep. 28, 2013
Derivatives and Fair Value Measurements [Abstract]
DERIVATIVES AND FAIR VALUE MEASUREMENTS	DERIVATIVES AND FAIR VALUE MEASUREMENTS
	We manufacture, market and sell our products globally. For the six months ended September 28, 2013, approximately 45.6% of our sales were generated outside the U.S. generally in local currencies. We also incur certain manufacturing, marketing and selling costs in international markets in local currency.
	Accordingly, our earnings and cash flows are exposed to market risk from changes in foreign currency exchange rates relative to the U.S. Dollar, our reporting currency. We have a program in place that is designed to mitigate our exposure to changes in foreign currency exchange rates. That program includes the use of derivative financial instruments to minimize for a period of time, the unforeseen impact on our financial results from changes in foreign exchange rates. We utilize foreign currency forward contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily the Japanese Yen and the Euro, and to a lesser extent the Swiss Franc, British Pound Sterling, Australian Dollar, Canadian Dollar and the Mexican Peso. This does not eliminate the volatility of foreign exchange rates, but because we generally enter into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation.
	Designated Foreign Currency Hedge Contracts
	All of our designated foreign currency hedge contracts as of September 28, 2013 and March 30, 2013 were cash flow hedges under ASC Topic 815, Derivatives and Hedging. We record the effective portion of any change in the fair value of designated foreign currency hedge contracts in Other Comprehensive Income until the related third-party transaction occurs. Once the related third-party transaction occurs, we reclassify the effective portion of any related gain or loss on the designated foreign currency hedge contracts to earnings. In the event the hedged forecasted transaction does not occur, or it becomes probable that it will not occur, we would reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. We had designated foreign currency hedge contracts outstanding in the contract amount of $126.8 million as of September 28, 2013 and $133.3 million as of March 30, 2013.
	During the six months ended September 28, 2013, a $1.7 million gain related to foreign exchange hedge contracts, net of tax, was recorded in Accumulated Other Comprehensive Income to recognize the effective portion of the fair value of any designated foreign currency hedge contracts that are, or previously were, designated as foreign currency cash flow hedges, as compared to net losses of $3.0 million, net of tax, for the six months ended September 29, 2012. At September 28, 2013, gains of $1.7 million, net of tax, may be reclassified to earnings within the next twelve months. All currency cash flow hedges outstanding as of September 28, 2013 mature within twelve months.
	Non-designated Foreign Currency Contracts
	We manage our exposure to changes in foreign currency on a consolidated basis to take advantage of offsetting transactions and balances. We use foreign currency forward contracts as a part of our strategy to manage exposure related to foreign currency denominated monetary assets and liabilities. These foreign currency forward contracts are entered into for periods consistent with currency transaction exposures, generally one month. They are not designated as cash flow or fair value hedges under ASC Topic 815. These forward contracts are marked-to-market with changes in fair value recorded to earnings. We had non-designated foreign currency hedge contracts under ASC Topic 815 outstanding in the contract amount of $80.2 million as of September 28, 2013 and $65.6 million as of March 30, 2013.
	Interest Rate Swaps
	On August 1, 2012, we entered into a credit agreement which provided for a $475.0 million term loan (“Credit Agreement”). Under the terms of this Credit Agreement, we may borrow at a spread to an index, including the LIBOR index of 1-month, 3-months, 6-months, etc. From the date of the Credit Agreement, we have chosen to borrow against the 1-month USD-LIBOR-BBA rounded up, if necessary, to the nearest 1/16th of 1% (“Adjusted LIBOR”). The terms of the Credit Agreement also allow us to borrow in multiple tranches. At the end of three months ended September 28, 2013 we had three tranches outstanding, each based on Adjusted LIBOR.
	Accordingly, our earnings and cash flows are exposed to interest rate risk from changes in Adjusted LIBOR. Part of our interest rate risk management strategy includes the use of interest rate swaps to mitigate our exposure to changes in variable interest rates. Our objective in using interest rate swaps is to add stability to interest expense and to manage and reduce the risk inherent in interest rate fluctuations. If the interest rate swap qualifies for hedge accounting, we formally document our hedge relationships (including identifying the hedged instrument and hedged item) at hedge inception. On a quarterly basis, we assess whether the interest rate swaps are highly effective in offsetting changes in the cash flow of the hedged item. We do not hold or issue interest rate swaps for trading purposes. We manage the credit risk of the counterparties by dealing only with institutions that we consider financially sound and consider the risk of non-performance to be remote.
	On December 21, 2012, we entered into two interest rate swap agreements ("The Swaps"), whereby we receive Adjusted LIBOR and pay an average fixed rate of 0.68% on a total notional amount of $250.0 million of debt. The Swaps mature on August 1, 2017. We designated The Swaps as cash flow hedges of variable interest rate risk associated with $250.0 million of indebtedness. For the six months ended September 28, 2013, a gain of $1.6 million, net of tax, was recorded in Accumulated Other Comprehensive Income to recognize the effective portion of the fair value of interest rate swaps that qualify as cash flow hedges.
	Fair Value of Derivative Instruments
	The following table presents the effect of our derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC Topic 815 in our consolidated statements of income and comprehensive income for the six months ended September 28, 2013.
	Derivative Instruments		Amount of				Amount of Gain/(Loss) Reclassified				Location in		Amount of Gain/(Loss)				Location in
			Gain/(Loss)				from AOCI into				Consolidated Statements of		Excluded from				Consolidated Statements of
			Recognized				Earnings				Income and Comprehensive Income		Effectiveness				Income and Comprehensive Income
			in AOCI				(Effective Portion)						Testing (*)
			(Effective Portion)
	(In thousands)
	Designated foreign currency hedge contracts, net of tax		$	1,704			$	4,602			Net revenues, COGS, and SG&A		$	33			Interest and other expense, net
	Non-designated foreign currency hedge contracts												(906		)		Interest and other expense, net
	Designated interest rate swaps, net of tax		$	1,643			$	577			Interest and other expense, net		$	—
	(*)   We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing.
	We did not have fair value hedges or net investment hedges outstanding as of September 28, 2013 or March 30, 2013.
	As of September 28, 2013, the amount recognized as deferred tax for designated foreign currency was $0.3 million and the amount recognized as deferred tax for interest rate swap hedges was $0.4 million.
	ASC Topic 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by ASC Topic 820, Fair Value Measurements and Disclosures, by considering the estimated amount we would receive or pay to sell or transfer these instruments at the reporting date and by taking into account current interest rates, currency exchange rates, current interest rate curves, interest rate volatilities, the creditworthiness of the counterparty for assets, and our creditworthiness for liabilities. In certain instances, we may utilize financial models to measure fair value. Generally, we use inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; other observable inputs for the asset or liability; and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of September 28, 2013, we have classified our derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by ASC Topic 815, as discussed below, because these observable inputs are available for substantially the full term of our derivative instruments.
	The following tables present the fair value of our derivative instruments as they appear in our consolidated balance sheets as of September 28, 2013 by type of contract and whether it is a qualifying hedge under ASC Topic 815.
	(In thousands)		Location in		September 28, 2013				March 30, 2013
			Balance Sheet
	Derivative Assets:
	Designated foreign currency hedge contracts		Other current assets		$	3,359			$	7,030
	Designated interest rate swaps		Other current assets		1,069				—
					$	4,428			$	7,030
	Derivative Liabilities:
	Designated foreign currency hedge contracts		Other current liabilities		$	1,436			$	954
	Designated interest rate swaps		Other current liabilities		—				671
					$	1,436			$	1,625
	Other Fair Value Measurements
	ASC Topic 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and expands disclosures about fair value measurements. ASC Topic 820 does not require any new fair value measurements; rather, it applies to other accounting pronouncements that require or permit fair value measurements. In accordance with ASC Topic 820, for the six months ended September 28, 2013, we applied the requirements under ASC Topic 820 to our non-financial assets and non-financial liabilities. As we did not have an impairment of any non-financial assets or non-financial liabilities, there was no disclosure required relating to our non-financial assets or non-financial liabilities.
	On a recurring basis, we measure certain financial assets and financial liabilities at fair value, including our money market funds, foreign currency hedge contracts, and contingent consideration. ASC Topic 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. We base fair value upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value.
	ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
	•	Level 1 — Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
	•	Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
	•	Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
	Our money market funds carried at fair value are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.
	Fair Value Measured on a Recurring Basis
	Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of September 28, 2013:
	(In thousands)		Quoted Market				Significant				Significant				Total
			Prices for				Other				Unobservable
			Identical Assets				Observable				Inputs
			(Level 1)				Inputs				(Level 3)
							(Level 2)
	Assets
	Money market funds		$	93,486			$	—			$	—			$	93,486
	Designated foreign currency hedge contracts		—				3,359				—				3,359
	Designated interest rate swap		—				1,069				—				1,069
			$	93,486			$	4,428			$	—			$	97,914
	Liabilities
	Designated foreign currency hedge contracts		$	—			$	1,436			$	—			$	1,436
	Contingent consideration		—				—				6,910				6,910
			$	—			$	1,436			$	6,910			$	8,346
	A description of the methods used to determine the fair value of the Level 3 liabilities is included within Note 3, Acquisitions. The table below provides a reconciliation of the beginning and ending Level 3 liabilities for the quarter ended September 28, 2013.
	(In thousands)		Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Beginning balance		$	6,600
Contingent consideration interest expense		310
Ending balance		$	6,910
Other Fair Value Disclosures
The Term Loan which is carried at amortized cost and accounts receivable and accounts payable approximate fair value.

INCOME_TAXES

INCOME TAXES	6 Months Ended
	Sep. 28, 2013
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES
	We conduct business globally and as a result report our results of operations in a number of foreign jurisdictions in addition to the United States.  Our reported tax rate is lower than the federal statutory rate in all reported periods as the income tax rates in the foreign jurisdictions are generally lower.
	The reported tax rates for the three and six months ended September 28, 2013 were 20.8% and 25.5%. The tax rate for the three months ended September 28, 2013 is lower than the tax rate for six months ended September 28, 2013 as during the first three months of the fiscal year we recorded significant pre-tax losses in Italy associated with restructuring costs and did not record a corresponding tax benefit due to uncertainty around our ability to realize tax benefits in Italy.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Sep. 28, 2013
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES
	We are presently engaged in various legal actions, and although ultimate liability cannot be determined at the present time, we believe, based on consultation with counsel, that any such liability will not materially affect our consolidated financial position or our results of operations.

SEGMENT_INFORMATION

SEGMENT INFORMATION	6 Months Ended
	Sep. 28, 2013
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION
	Segment Definition Criteria
	We manage our business on the basis of one operating segment: the design, manufacture, and marketing of blood management solutions. Our chief operating decision-maker uses consolidated results to make operating and strategic decisions. Manufacturing processes, as well as the regulatory environment in which we operate, are largely the same for all product categories.
	Enterprise-Wide Disclosures about Product and Services
	We have four global product families: plasma, blood center, hospital, and software solutions.
	Our products include whole blood disposables, equipment devices and the related disposables used with these devices. Disposables include part of plasma, blood center, and hospital product families. Plasma consists of the disposables used to perform apheresis for the separation of whole blood components and subsequent collection of plasma to be used as a raw material for biologically derived pharmaceuticals. Blood center consists of disposables which separate whole blood for the subsequent collection of platelets, plasma, red cells, or a combination of these components for transfusion to patients as well as disposables for manual whole blood collection. Hospital consists of surgical disposables (principally the Cell Saver® autologous blood recovery system targeted to procedures that involve rapid, high volume blood loss such as cardiovascular surgeries and the cardioPAT® cardiovascular perioperative autotransfusion system designed to remain with the patient following surgery to recover blood and the patient’s red cells to prepare them for reinfusion), the OrthoPAT® orthopedic perioperative autotransfusion system designed to operate both during and after surgery to recover and wash the patient’s red cells to prepare them for reinfusion, and diagnostics products (principally the TEG® Thrombelastograph® hemostasis analyzer used to help assess a surgical patient’s hemostasis during and after surgery). Software solutions include information technology platforms that assist blood centers, plasma centers, and hospitals to more effectively manage regulatory compliance and operational efficiency.
	Revenues from External Customers:
		Three Months Ended
	(In thousands)	September 28,		September 29,
		2013		2012
	Disposable revenues
	Plasma disposables	$	75,734	$	68,677
	Blood center disposables
	Platelet	39,884		43,198
	Red cell	10,221		11,918
	Whole blood	47,283		28,620
		97,388		83,736
	Hospital disposables
	Surgical	16,351		18,804
	OrthoPAT	6,262		7,645
	Diagnostics	7,985		6,937
		30,598		33,386
	Total disposables revenue	203,720		185,799
	Software solutions	17,120		18,043
	Equipment & other	14,915		14,336
	Net revenues	$	235,755	$	218,178
		Six Months Ended
	(In thousands)	September 28, 2013		September 29, 2012
	Disposable revenues
	Plasma disposables	$	141,070	$	132,555
	Blood center disposables
	Platelet	74,330		80,440
	Red cell	20,229		23,986
	Whole blood	98,537		28,620
		193,096		133,046
	Hospital disposables
	Surgical	32,441		37,064
	OrthoPAT	12,581		15,186
	Diagnostics	15,579		13,436
		60,601		65,686
	Total disposables revenue	394,767		331,287
	Software solutions	33,866		35,347
	Equipment & other	26,664		28,019
	Net revenues	$	455,297	$	394,653

RESTRUCTURING

RESTRUCTURING	6 Months Ended
	Sep. 28, 2013
Restructuring and Related Activities [Abstract]
REORGANIZATION	RESTRUCTURING
	On an ongoing basis, we review the global economy, the healthcare industry, and the markets in which we compete. From these reviews we identify opportunities to improve efficiencies, enhance commercial capabilities, better align our resources and offer customers better comprehensive solutions. In order to realize these opportunities, from time to time, we undertake restructuring and other initiatives to transform our business.
	On May 1, 2013 we announced that our Board of Directors has approved a plan to pursue identified Value Creation & Capture (“VCC”) opportunities. These include: (i) investment in product line extensions, next generation products and growth platforms; (ii) enhancement of commercial execution capabilities by implementing go-to-market and other strategies to enable global profitable revenue growth; and (iii) transformation of the manufacturing network to best support these commercial strategies while optimizing expense levels. Collectively, these are opportunities to position us for optimal growth and increased competitiveness.
	Transformation of the manufacturing network will take place through fiscal 2016, and will involve (i) discontinuing manufacturing activities at our Braintree, Massachusetts and Ascoli-Piceno, Italy locations, (ii) creating a technology center of excellence for product development close to our current Corporate Headquarters, (iii) expansion of our current facility in Tijuana, Mexico, (iv) engaging Sanmina Corporation as a contract manufacturer to produce certain medical equipment, and (v) building a new manufacturing facility in Penang, Malaysia closer to our customers in Asia.
	For the six months ended September 28, 2013, we incurred $30.3 million of restructuring charges of which $11.6 million is payable within the next twelve months. The substantial majority of restructuring expenses have been included as a component of selling, general and administrative expense in the accompanying consolidated statements of income and comprehensive income.
	The following summarizes the restructuring activity for the six months ended September 28, 2013 and September 29, 2012:
		Six Months Ended September 28, 2013
	(In thousands)		Restructuring Accrual Balance at March 30, 2013		Restructuring Costs Incurred		Payments			Asset Write-Down			Restructuring Accrual Balance at September 28, 2013
	Severance and other employee costs		$	3,089	$	22,841	$	(6,565	)	$	—		$	19,365
	Other costs		173		5,317		(5,065		)	—			425
	Accelerated depreciation		—		1,188		—			(1,188		)	—
	Asset write-down		—		915		—			(915		)	—
	Total		$	3,262	$	30,261	$	(11,630	)	$	(2,103	)	$	19,790
			Six Months Ended September 29, 2012
	(in thousands)		Restructuring Accrual Balance at March 31, 2012		Restructuring Costs Incurred		Payments			Asset Write-Down			Restructuring Accrual Balance at September 29, 2012
	Severance and other employee costs		$	1,461	$	2,070	$	(1,734	)	$	—		$	1,797
	Other costs		533		209		(703		)	—			39
	Total		$	1,994	$	2,279	$	(2,437	)	$	—		$	1,836
	We expect to deploy significant financial resources for these activities.  Many of the activities necessary to complete the VCC initiatives include severance and other costs which qualify as restructuring expenses under ASC 420, Exit or Disposal Cost Obligations.  We anticipate we will incur approximately $71.0 million in severance, asset write-offs and other restructuring charges as well as other “Transformation Costs” related to VCC initiatives in fiscal 2014.  The majority of these costs relate to the discontinuation of manufacturing activities in Braintree, Massachusetts and Ascoli-Piceno, Italy, and will be incurred in the current fiscal year.
	In addition, we also incur costs that do not constitute restructuring under ASC 420, Exit or Disposal Cost Obligations which we refer to as "Transformation Costs". These costs consist primarily of expenditures directly related to our transformation activities including program management, integration and product line transfer teams, infrastructure related costs, accelerated depreciation and asset disposals.  Additionally, costs incurred in three months ended September 28, 2013 include $3.6 million of in-process research and development charges related to the acquisition of certain technology and manufacturing rights to be used in a next generation device. The table below presents transformation and restructuring costs recorded in cost of goods sold, research and development, selling, general and administrative expenses and interest and other expense in our statement of income and comprehensive income for the periods presented. The majority of expenses recorded as Transformation Costs in both the prior and current year relate to the acquisition and integration of Pall's transfusion medicine business, which was purchased for $535.1 million in August 2012. We anticipate that we will incur approximately $82.0 million in total restructuring and transformation expenses related to VCC initiatives and completion of whole blood integration activities in fiscal 2014 of which $72 million is payable in cash.
	Transformation costs		Three Months Ended				Six Months Ended
	(in thousands)		September 28, 2013		September 29,		September 28, 2013			September 29,
					2012					2012
	Integration and other costs		$	10,868	$	22,193	$	20,083		$	27,826
	Accelerated depreciation		442		—		1,285			—
	Asset disposal		760		—		760			—
	Total		$	12,070	$	22,193	$	22,128		$	27,826
	Restructuring costs		Three Months Ended				Six Months Ended
	(in thousands)		September 28, 2013		September 29,		September 28, 2013			September 29,
					2012					2012
	Severance and other employee costs		$	2,606	$	1,379	$	22,841		$	2,070
	Other costs		2,676		95		5,317			209
	Accelerated depreciation		934		—		1,188			—
	Asset disposal		586		—		915			—
	Total		$	6,802	$	1,474	$	30,261		$	2,279
	Total restructuring and transformation		$	18,872	$	23,667	$	52,389		$	30,105

CAPITALIZATION_OF_SOFTWARE_DEV

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	6 Months Ended
	Sep. 28, 2013
Capitalization of Software and Development Costs [Abstract]
CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS
	For costs incurred related to the development of software to be sold, leased, or otherwise marketed, we apply the provisions of ASC Topic 985-20, Software - Costs of Software to be Sold, Leased or Marketed, which specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers.
	We capitalized $2.6 million and $3.2 million in software development costs for ongoing initiatives during the six month periods ended September 28, 2013 and September 29, 2012, respectively. At September 28, 2013 and March 30, 2013, we have a total of $22.6 million and $20.0 million, respectively, of costs capitalized related to in-process software development initiatives. The costs capitalized for each project are included in intangible assets in the consolidated financial statements. We review these assets for impairment annually.

ACCUMULATED_OTHER_COMPREHENSIV

ACCUMULATED OTHER COMPREHENSIVE INCOME	6 Months Ended
	Sep. 28, 2013
Stockholders' Equity Note [Abstract]
ACCUMULATED OTHER COMPREHENSIVE INCOME	ACCUMULATED OTHER COMPREHENSIVE INCOME
	The following is a roll forward of the components of Accumulated Other Comprehensive Income, net of tax, for the six months ended September 28, 2013:
	(In thousands)	Foreign currency			Defined benefit plans			Net Unrealized Gain/loss on Derivatives			Total
	Balance as of March 30, 2013	$	4,133		$	(5,073	)	$	6,373		$	5,433
	Other comprehensive income before reclassifications	332						3,346			3,678
	Amounts reclassified from Accumulated Other Comprehensive Income	—						(5,179		)	(5,179		)
	Net current period other comprehensive income	332			—			(1,833		)	(1,501		)
	Balance as of September 28, 2013	$	4,465		$	(5,073	)	$	4,540		$	3,932
	The details about the amount reclassified from Accumulated other comprehensive income for the six months ended September 28, 2013 are as follows:
	(In thousands)	Amounts Reclassified from Other Comprehensive Income			Affected Line in the
					Statement of Income
	Derivative instruments reclassified to income statement
	Realized net gain on derivatives	$	5,458		Revenue, cost of goods sold, income/(expense)
	Income tax effect	(279		)	Provision for income taxes
	Net of taxes	$	5,179

ACQUISITIONS_Tables

ACQUISITIONS (Tables) (Hemerus Medical, LLC [Member])	6 Months Ended
	Sep. 28, 2013
Hemerus Medical, LLC [Member]
Business Acquisition [Line Items]
Schedule of Purchase Price Allocation	The preliminary purchase price allocation is as follows:
	Asset class	Amounts Recognized as of September 28, 2013
	(In thousands)
	Intangible assets	$	20,400
	Goodwill	10,324
	Fair value of net assets acquired	$	30,724

EARNINGS_PER_SHARE_EPS_Tables

EARNINGS PER SHARE ("EPS") (Tables)	6 Months Ended
	Sep. 28, 2013
Earnings Per Share [Abstract]
Schedule of Earnings Per Share Reconciliation	The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations. Basic EPS is computed by dividing net income by weighted average shares outstanding. Diluted EPS includes the effect of potentially dilutive common shares. The common stock weighted average number of shares has been retroactively adjusted for the stock split that occurred on November 30, 2012.
		Three Months Ended
	(In thousands, except per share amounts)	September 28,		September 29,
		2013		2012
	Basic EPS
	Net income	$	16,548	$	6,547
	Weighted average shares	51,492		51,420
	Basic income per share	$	0.32	$	0.13
	Diluted EPS
	Net income	$	16,548	$	6,547
	Basic weighted average shares	51,492		51,420
	Net effect of common stock equivalents	869		894
	Diluted weighted average shares	52,361		52,314
	Diluted income per share	$	0.32	$	0.13
		Six Months Ended
	(In thousands, except per share amounts)	September 28, 2013		September 29, 2012
	Basic EPS
	Net income	$	8,674	$	16,335
	Weighted average shares	51,360		51,192
	Basic income per share	$	0.17	$	0.32
	Diluted EPS
	Net income	$	8,674	$	16,335
	Basic weighted average shares	51,360		51,192
	Net effect of common stock equivalents	840		896
	Diluted weighted average shares	52,200		52,088
	Diluted income per share	$	0.17	$	0.31

STOCKBASED_COMPENSATION_Tables

STOCK-BASED COMPENSATION (Tables)	6 Months Ended
	Sep. 28, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Assumptions Utilized for Estimating Fair Value of Option Grants	The assumptions utilized for estimating the fair value of option grants during the periods presented are as follows:
		Six Months Ended
		September 28,		September 29,
		2013		2012
	Stock Options Black-Scholes assumptions (weighted average):
	Volatility	25.49	%	27.18	%
	Expected life (years)	5		5
	Risk-free interest rate	1.4	%	0.62	%
	Dividend yield	—	%	—	%

PRODUCT_WARRANTIES_Tables

PRODUCT WARRANTIES (Tables)	6 Months Ended
	Sep. 28, 2013
Product Warranties Disclosures [Abstract]
Schedule of Product Warranty Liability	We estimate our potential warranty expense based on our historical warranty experience, and we periodically assess the adequacy of our warranty accrual and make adjustments as necessary.
		Six Months Ended
	(In thousands)	September 28,			September 29,
		2013			2012
	Warranty accrual as of the beginning of the period	$	673		$	796
	Warranty provision	775			806
	Warranty spending	(723		)	(886		)
	Warranty accrual as of the end of the period	$	725		$	716

INVENTORIES_Tables

INVENTORIES (Tables)	6 Months Ended
	Sep. 28, 2013
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined on the first-in, first-out method.
	(In thousands)	September 28, 2013		30-Mar-13
	Raw materials	$	77,348	$	70,716
	Work-in-process	7,292		7,829
	Finished goods	120,611		105,239
		$	205,251	$	183,784

DERIVATIVES_AND_FAIR_VALUE_MEA1

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Sep. 28, 2013
Derivatives and Fair Value Measurements [Abstract]
Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments	The following table presents the effect of our derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC Topic 815 in our consolidated statements of income and comprehensive income for the six months ended September 28, 2013.
	Derivative Instruments	Amount of				Amount of Gain/(Loss) Reclassified				Location in		Amount of Gain/(Loss)				Location in
		Gain/(Loss)				from AOCI into				Consolidated Statements of		Excluded from				Consolidated Statements of
		Recognized				Earnings				Income and Comprehensive Income		Effectiveness				Income and Comprehensive Income
		in AOCI				(Effective Portion)						Testing (*)
		(Effective Portion)
	(In thousands)
	Designated foreign currency hedge contracts, net of tax	$	1,704			$	4,602			Net revenues, COGS, and SG&A		$	33			Interest and other expense, net
	Non-designated foreign currency hedge contracts											(906		)		Interest and other expense, net
	Designated interest rate swaps, net of tax	$	1,643			$	577			Interest and other expense, net		$	—
	(*)   We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing.
Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets	The following tables present the fair value of our derivative instruments as they appear in our consolidated balance sheets as of September 28, 2013 by type of contract and whether it is a qualifying hedge under ASC Topic 815.
	(In thousands)	Location in		September 28, 2013				March 30, 2013
		Balance Sheet
	Derivative Assets:
	Designated foreign currency hedge contracts	Other current assets		$	3,359			$	7,030
	Designated interest rate swaps	Other current assets		1,069				—
				$	4,428			$	7,030
	Derivative Liabilities:
	Designated foreign currency hedge contracts	Other current liabilities		$	1,436			$	954
	Designated interest rate swaps	Other current liabilities		—				671
				$	1,436			$	1,625
Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis	Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of September 28, 2013:
	(In thousands)	Quoted Market				Significant				Significant				Total
		Prices for				Other				Unobservable
		Identical Assets				Observable				Inputs
		(Level 1)				Inputs				(Level 3)
						(Level 2)
	Assets
	Money market funds	$	93,486			$	—			$	—			$	93,486
	Designated foreign currency hedge contracts	—				3,359				—				3,359
	Designated interest rate swap	—				1,069				—				1,069
		$	93,486			$	4,428			$	—			$	97,914
	Liabilities
	Designated foreign currency hedge contracts	$	—			$	1,436			$	—			$	1,436
	Contingent consideration	—				—				6,910				6,910
		$	—			$	1,436			$	6,910			$	8,346
Schedule of Fair Value Measurements Using Significant Unobservable Inputs (Level 3)	A description of the methods used to determine the fair value of the Level 3 liabilities is included within Note 3, Acquisitions. The table below provides a reconciliation of the beginning and ending Level 3 liabilities for the quarter ended September 28, 2013.
	(In thousands)	Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
	Beginning balance	$	6,600
	Contingent consideration interest expense	310
	Ending balance	$	6,910

SEGMENT_INFORMATION_Tables

SEGMENT INFORMATION (Tables)	6 Months Ended
	Sep. 28, 2013
Segment Reporting [Abstract]
Schedule of Revenues from External Customers	Revenues from External Customers:
		Three Months Ended
	(In thousands)	September 28,		September 29,
		2013		2012
	Disposable revenues
	Plasma disposables	$	75,734	$	68,677
	Blood center disposables
	Platelet	39,884		43,198
	Red cell	10,221		11,918
	Whole blood	47,283		28,620
		97,388		83,736
	Hospital disposables
	Surgical	16,351		18,804
	OrthoPAT	6,262		7,645
	Diagnostics	7,985		6,937
		30,598		33,386
	Total disposables revenue	203,720		185,799
	Software solutions	17,120		18,043
	Equipment & other	14,915		14,336
	Net revenues	$	235,755	$	218,178
		Six Months Ended
	(In thousands)	September 28, 2013		September 29, 2012
	Disposable revenues
	Plasma disposables	$	141,070	$	132,555
	Blood center disposables
	Platelet	74,330		80,440
	Red cell	20,229		23,986
	Whole blood	98,537		28,620
		193,096		133,046
	Hospital disposables
	Surgical	32,441		37,064
	OrthoPAT	12,581		15,186
	Diagnostics	15,579		13,436
		60,601		65,686
	Total disposables revenue	394,767		331,287
	Software solutions	33,866		35,347
	Equipment & other	26,664		28,019
	Net revenues	$	455,297	$	394,653

RESTRUCTURING_Tables

RESTRUCTURING (Tables)	6 Months Ended
	Sep. 28, 2013
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve by Type of Cost	The following summarizes the restructuring activity for the six months ended September 28, 2013 and September 29, 2012:
		Six Months Ended September 28, 2013
	(In thousands)		Restructuring Accrual Balance at March 30, 2013		Restructuring Costs Incurred		Payments			Asset Write-Down			Restructuring Accrual Balance at September 28, 2013
	Severance and other employee costs		$	3,089	$	22,841	$	(6,565	)	$	—		$	19,365
	Other costs		173		5,317		(5,065		)	—			425
	Accelerated depreciation		—		1,188		—			(1,188		)	—
	Asset write-down		—		915		—			(915		)	—
	Total		$	3,262	$	30,261	$	(11,630	)	$	(2,103	)	$	19,790
			Six Months Ended September 29, 2012
	(in thousands)		Restructuring Accrual Balance at March 31, 2012		Restructuring Costs Incurred		Payments			Asset Write-Down			Restructuring Accrual Balance at September 29, 2012
	Severance and other employee costs		$	1,461	$	2,070	$	(1,734	)	$	—		$	1,797
	Other costs		533		209		(703		)	—			39
	Total		$	1,994	$	2,279	$	(2,437	)	$	—		$	1,836
Schedule of Restructuring and Related Costs
	Transformation costs		Three Months Ended				Six Months Ended
	(in thousands)		September 28, 2013		September 29,		September 28, 2013			September 29,
					2012					2012
	Integration and other costs		$	10,868	$	22,193	$	20,083		$	27,826
	Accelerated depreciation		442		—		1,285			—
	Asset disposal		760		—		760			—
	Total		$	12,070	$	22,193	$	22,128		$	27,826
	Restructuring costs		Three Months Ended				Six Months Ended
	(in thousands)		September 28, 2013		September 29,		September 28, 2013			September 29,
					2012					2012
	Severance and other employee costs		$	2,606	$	1,379	$	22,841		$	2,070
	Other costs		2,676		95		5,317			209
	Accelerated depreciation		934		—		1,188			—
	Asset disposal		586		—		915			—
	Total		$	6,802	$	1,474	$	30,261		$	2,279
	Total restructuring and transformation		$	18,872	$	23,667	$	52,389		$	30,105

COMPREHENSIVE_INCOME_Tables

COMPREHENSIVE INCOME (Tables)	6 Months Ended
	Sep. 28, 2013
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The following is a roll forward of the components of Accumulated Other Comprehensive Income, net of tax, for the six months ended September 28, 2013:
	(In thousands)	Foreign currency			Defined benefit plans			Net Unrealized Gain/loss on Derivatives			Total
	Balance as of March 30, 2013	$	4,133		$	(5,073	)	$	6,373		$	5,433
	Other comprehensive income before reclassifications	332						3,346			3,678
	Amounts reclassified from Accumulated Other Comprehensive Income	—						(5,179		)	(5,179		)
	Net current period other comprehensive income	332			—			(1,833		)	(1,501		)
	Balance as of September 28, 2013	$	4,465		$	(5,073	)	$	4,540		$	3,932
Reclassification out of Accumulated Other Comprehensive Income	The details about the amount reclassified from Accumulated other comprehensive income for the six months ended September 28, 2013 are as follows:
	(In thousands)	Amounts Reclassified from Other Comprehensive Income			Affected Line in the
					Statement of Income
	Derivative instruments reclassified to income statement
	Realized net gain on derivatives	$	5,458		Revenue, cost of goods sold, income/(expense)
	Income tax effect	(279		)	Provision for income taxes
	Net of taxes	$	5,179

BASIS_OF_PRESENTATION_Narrativ

BASIS OF PRESENTATION (Narrative) (Details)	6 Months Ended	12 Months Ended
	Sep. 28, 2013	Mar. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Term of each fiscal quarter	364 days	364 days
Term of each quarter	91 days	91 days

ACQUISITIONS_Details

ACQUISITIONS (Details) (Hemerus Medical, LLC [Member], USD $)	Sep. 28, 2013	Mar. 30, 2013
Business Acquisition [Line Items]
Business acquisition, cash paid		$24,100,000
Asset class
Intangible assets	20,400,000
Goodwill	10,324,000
Fair value of net assets acquired	30,724,000
FDA Approval of SOLX [Member]
Business Acquisition [Line Items]
Contingent consideration, maximum		3,000,000
Future Sales of SOLX [Member]
Business Acquisition [Line Items]
Contingent consideration, maximum		$14,000,000

EARNINGS_PER_SHARE_EPS_Schedul

EARNINGS PER SHARE ("EPS") (Schedule of Earnings Per Share Reconciliation) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012
Basic EPS
Net income	$16,548	$6,547	$8,674	$16,335
Basic weighted average shares (in shares)	51,492,000	51,420,000	51,360,000	51,192,000
Basic income per share (in dollars per share)	$0.32	$0.13	$0.17	$0.32
Diluted EPS
Net income	$16,548	$6,547	$8,674	$16,335
Basic weighted average shares (in shares)	51,492,000	51,420,000	51,360,000	51,192,000
Net effect of common stock equivalents (in shares)	869,000	894,000	840,000	896,000
Diluted weighted average shares (in shares)	52,361,000	52,314,000	52,200,000	52,088,000
Diluted income per share (in dollars per share)	$0.32	$0.13	$0.17	$0.31
Stock options excluded from computation of weighted average shares outstanding (in shares)	800,000	100,000	800,000	400,000

STOCKBASED_COMPENSATION_Detail

STOCK-BASED COMPENSATION (Details) (USD $)	6 Months Ended		3 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013
			Market Stock Units [Member]
			times
			senior_executive
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized	$6.40	$5
Tax benefit from compensaton expense	2.1	1.6
Weighted average fair value of options granted (in dollars per share)	$10.98	$9.01
Grants in period (in shares)			300,000
Number of senior executives			13
Performance shares threshold (in dollars per share)			$50
Shares received below threshold price (in shares)			0
Performance shares maximum multiplier			3
Minimum stock price if performance shares issued (in dollars per share)			$85
Maximum shares authorized (in shares)			900,000
Performance shares fair value			$11.20
Stock Options Black-Scholes assumptions (weighted average):
Fair value (in dollars per share)			$37.42
Volatility	25.49%	27.18%	20.00%
Expected life (years)	5 years	5 years	3 years 8 months 12 days
Risk-free interest rate	1.40%	0.62%	0.90%
Dividend yield	0.00%	0.00%	0.00%
Shares purchased under the ESPP (in shares)	81,465	84,514
Shares purchased under the ESPP (in dollars per share)	$32.73	$24.92

PRODUCT_WARRANTIES_Schedule_of

PRODUCT WARRANTIES (Schedule of Product Warranty Liability) (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Mar. 30, 2013
Product Warranties [Roll Forward]
Warranty accrual as of the beginning of the period		$796	$673
Warranty provision	775	806
Warranty spending	-723	-886
Warranty accrual as of the end of the period	$725	$716	$673

INVENTORIES_Schedule_of_Invent

INVENTORIES (Schedule of Inventories) (Details) (USD $)	Sep. 28, 2013	Mar. 30, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Raw materials	$77,348	$70,716
Work-in-process	7,292	7,829
Finished goods	120,611	105,239
Inventories, net	$205,251	$183,784

DERIVATIVES_AND_FAIR_VALUE_MEA2

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments) (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013
Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Contract
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Loss Recognized in AOCI (Effective Portion)	$1,704
Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Contract | Net revenues, COGS, and SG&A
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Loss Reclassifiedfrom AOCI into Earnings (Effective Portion)	4,602
Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Contract | Other Income (Expense), Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount Excluded from Effectiveness Testing	33	[1]
Designated as Hedging Instrument | Interest Rate Swap [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Loss Recognized in AOCI (Effective Portion)	1,643
Amount Excluded from Effectiveness Testing	0	[1]
Designated as Hedging Instrument | Interest Rate Swap [Member] | Interest Income (Expense), Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Loss Reclassifiedfrom AOCI into Earnings (Effective Portion)	577
Not Designated as Hedging Instrument | Foreign Exchange Contract
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Loss Recognized in AOCI (Effective Portion)
Amount of Loss Reclassifiedfrom AOCI into Earnings (Effective Portion)
Not Designated as Hedging Instrument | Foreign Exchange Contract | Other Income (Expense), Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount Excluded from Effectiveness Testing	($906)	[1]
[1]	We exclude the difference between the spot rate and hedge forward rate from our effectiveness testing.

DERIVATIVES_AND_FAIR_VALUE_MEA3

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets) (Details) (USD $)	Sep. 28, 2013	Mar. 30, 2013
In Thousands, unless otherwise specified
Derivative Assets:
Derivative Assets	$4,428	$7,030
Derivative Liabilities:
Derivative Liabilities	1,436	1,625
Designated as Hedging Instrument | Foreign Exchange Contract | Other Current Assets
Derivative Assets:
Derivative Assets	3,359	7,030
Designated as Hedging Instrument | Foreign Exchange Contract | Other Current Liabilities
Derivative Liabilities:
Derivative Liabilities	1,436	954
Designated as Hedging Instrument | Interest Rate Swap [Member] | Other Current Assets
Derivative Assets:
Derivative Assets	1,069	0
Designated as Hedging Instrument | Interest Rate Swap [Member] | Other Current Liabilities
Derivative Liabilities:
Derivative Liabilities	$0	$671

DERIVATIVES_AND_FAIR_VALUE_MEA4

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Financial Assets and Financial Liabilities Measured at Fair Value) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013
Assets
Money market funds	$93,486
Designated foreign currency hedge contracts	3,359
Designated interest rate swap	1,069
Assets, Fair Value Disclosure, Total	97,914
Liabilities
Designated foreign currency hedge contracts	1,436
Contingent consideration	6,910
Liabilities, Fair Value Disclosure	8,346
Quoted Market Prices for Identical Assets (Level 1)
Assets
Money market funds	93,486
Designated foreign currency hedge contracts	0
Designated interest rate swap	0
Assets, Fair Value Disclosure, Total	93,486
Liabilities
Designated foreign currency hedge contracts	0
Contingent consideration	0
Liabilities, Fair Value Disclosure	0
Significant Other Observable Inputs (Level 2)
Assets
Money market funds	0
Designated foreign currency hedge contracts	3,359
Designated interest rate swap	1,069
Assets, Fair Value Disclosure, Total	4,428
Liabilities
Designated foreign currency hedge contracts	1,436
Contingent consideration	0
Liabilities, Fair Value Disclosure	1,436
Significant Unobservable Inputs (Level 3)
Assets
Money market funds	0
Designated foreign currency hedge contracts	0
Designated interest rate swap	0
Assets, Fair Value Disclosure, Total	0
Liabilities
Designated foreign currency hedge contracts	0
Contingent consideration	6,910
Liabilities, Fair Value Disclosure	6,910
Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Beginning balance	6,600
Contingent consideration interest expense	310
Ending balance	$6,910

DERIVATIVES_AND_FAIR_VALUE_MEA5

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Narrative) (Details) (USD $)	6 Months Ended		6 Months Ended			0 Months Ended	6 Months Ended		0 Months Ended
	Sep. 28, 2013	Mar. 30, 2013	Sep. 28, 2013	Sep. 28, 2013	Sep. 28, 2013	Dec. 21, 2012	Sep. 28, 2013	Sep. 28, 2013	Aug. 03, 2012	Aug. 01, 2012
			Designated as Hedging Instrument	Designated as Hedging Instrument	Designated as Hedging Instrument	Designated as Hedging Instrument	Designated as Hedging Instrument	Foreign Country	Term Loan [Member]	Term Loan [Member]
			Foreign Exchange Contract	Interest Rate Swap [Member]	Cash Flow Hedging	Interest Rate Swap [Member]	Interest Rate Swap [Member]
					Foreign Exchange Contract
Derivative [Line Items]
Percentage of sales generated outside the US								45.60%
Maturity period for foreign currency contracts (in years)	1 year
Designated foreign currency hedge contracts outstanding	$126,800,000	$133,300,000
Recognized net losses in earnings on cash flow hedges					-3,000,000
Non-designated foreign currency hedge contracts outstanding	80,200,000	65,600,000
Fair value of real estate mortgage obligation	8,346,000
Face amount of debt										475,000,000
Description of variable rate basis						LIBOR			1-month USD-LIBOR-BBA rounded up, if necessary, to the nearest 1/16th of 1% (“Adjusted LIBOR”)
Derivative, fixed interest rate						0.68%
Deferred income tax expense (benefit)			300,000	400,000
Derivative, Notional Amount						250,000,000
Amount of Loss Recognized in AOCI (Effective Portion)					$1,704,000		$1,643,000

INCOME_TAXES_Details

INCOME TAXES (Details)	3 Months Ended	6 Months Ended
	Sep. 28, 2013	Sep. 28, 2013
Income Tax Disclosure [Abstract]
Reported tax rate	20.80%	25.50%

SEGMENT_INFORMATION_Revenues_f

SEGMENT INFORMATION (Revenues from External Customers) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012
Revenue from External Customer [Line Items]
Net revenues	$235,755	$218,178	$455,297	$394,653
Reportable Segment [Member]
Revenue from External Customer [Line Items]
Net revenues			394,767	331,287
Reportable Segment [Member] | Plasma Disposables [Member]
Revenue from External Customer [Line Items]
Net revenues	75,734	68,677	141,070	132,555
Reportable Segment [Member] | Blood Center [Member]
Revenue from External Customer [Line Items]
Net revenues	97,388	83,736	193,096	133,046
Reportable Segment [Member] | Platelet [Member]
Revenue from External Customer [Line Items]
Net revenues	39,884	43,198	74,330	80,440
Reportable Segment [Member] | Red Cell [Member]
Revenue from External Customer [Line Items]
Net revenues	10,221	11,918	20,229	23,986
Reportable Segment [Member] | Whole Blood [Member]
Revenue from External Customer [Line Items]
Net revenues	47,283	28,620	98,537	28,620
Reportable Segment [Member] | Hospital [Member]
Revenue from External Customer [Line Items]
Net revenues	30,598	33,386	60,601	65,686
Reportable Segment [Member] | Surgical [Member]
Revenue from External Customer [Line Items]
Net revenues	16,351	18,804	32,441	37,064
Reportable Segment [Member] | OrthoPAT [Member]
Revenue from External Customer [Line Items]
Net revenues	6,262	7,645	12,581	15,186
Reportable Segment [Member] | Diagnostics [Member]
Revenue from External Customer [Line Items]
Net revenues	7,985	6,937	15,579	13,436
Reportable Segment [Member] | Disposables Revenue [Member]
Revenue from External Customer [Line Items]
Net revenues	203,720	185,799
Reportable Segment [Member] | Software Solutions [Member]
Revenue from External Customer [Line Items]
Net revenues	17,120	18,043	33,866	35,347
Reportable Segment [Member] | Equipment and Other [Member]
Revenue from External Customer [Line Items]
Net revenues	$14,915	$14,336	$26,664	$28,019

RESTRUCTURING_Narrative_Detail

RESTRUCTURING (Narrative) (Details) (USD $)	3 Months Ended		6 Months Ended			3 Months Ended
	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 28, 2013	Aug. 01, 2012
					Transformation of Manufacturing Network [Member]	Acquisition Related Research and Development [Member]	Pall Corporation [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges expected to be incured	$82,000,000				$71,000,000
Restructuring Costs Incurred	6,802,000	1,474,000	30,261,000	2,279,000		3,600,000
Restructuring charges payable in next twelve months	11,600,000		11,600,000
Purchase of business							535,100,000
Restructuring charges expected to be incured in fiscal 2014 payable in cash	$72,000,000

RESTRUCTURING_Schedule_of_Rest

RESTRUCTURING (Schedule of Restructuring Reserve by Type of Cost) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012	Mar. 30, 2013
Restructuring Reserve [Roll Forward]
Beginning Balance				$1,994	$3,262
Restructuring Costs Incurred	6,802	1,474	30,261	2,279
Payments			-11,630	-2,437
Asset Write-Down			-2,103	0
Ending Balance	19,790	1,836	19,790	1,836	3,262
Severance and other employee costs
Restructuring Reserve [Roll Forward]
Beginning Balance				1,461	3,089
Restructuring Costs Incurred	2,606	1,379	22,841	2,070
Payments			-6,565	-1,734
Asset Write-Down			0	0
Ending Balance	19,365	1,797	19,365	1,797	3,089
Other costs
Restructuring Reserve [Roll Forward]
Beginning Balance				533	173
Restructuring Costs Incurred	2,676	95	5,317	209
Payments			-5,065	-703
Asset Write-Down			0	0
Ending Balance	425	39	425	39	173
Accelerated depreciation
Restructuring Reserve [Roll Forward]
Beginning Balance					0
Restructuring Costs Incurred	934	0	1,188	0
Payments			0
Asset Write-Down			-1,188
Ending Balance	0		0		0
Asset write-down
Restructuring Reserve [Roll Forward]
Beginning Balance					0
Restructuring Costs Incurred			915
Payments			0
Asset Write-Down			-915
Ending Balance	$0		$0		$0

RESTRUCTURING_Schedule_of_Rest1

RESTRUCTURING (Schedule of Restructuring and Related Costs) (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012
Restructuring Cost and Reserve [Line Items]
Transformation costs	$12,070	$22,193	$22,128	$27,826
Restructuring Costs Incurred	6,802	1,474	30,261	2,279
Total restructuring and transformation	18,872	23,667	52,389	30,105
Severance and other employee costs
Restructuring Cost and Reserve [Line Items]
Restructuring Costs Incurred	2,606	1,379	22,841	2,070
Other costs
Restructuring Cost and Reserve [Line Items]
Restructuring Costs Incurred	2,676	95	5,317	209
Accelerated depreciation
Restructuring Cost and Reserve [Line Items]
Restructuring Costs Incurred	934	0	1,188	0
Asset disposal
Restructuring Cost and Reserve [Line Items]
Restructuring Costs Incurred	586	0	915	0
Integration and other costs
Restructuring Cost and Reserve [Line Items]
Transformation costs	10,868	22,193	20,083	27,826
Accelerated depreciation
Restructuring Cost and Reserve [Line Items]
Transformation costs	442	0	1,285	0
Asset disposal
Restructuring Cost and Reserve [Line Items]
Transformation costs	$760	$0	$760	$0

CAPITALIZATION_OF_SOFTWARE_DEV1

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS (Narrative) (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Mar. 30, 2013
Capitalization of Software and Development Costs [Abstract]
Capitalized software development costs for ongoing initiatives	$2.60	$3.20
Total costs capitalized related to in process software development initiatives	$22.60		$20

ACCUMULATED_OTHER_COMPREHENSIV1

ACCUMULATED OTHER COMPREHENSIVE INCOME (Details 1) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Mar. 30, 2013
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance as of March 30, 2013		$5,433
Other comprehensive income before reclassifications	3,678
Amounts reclassified from Accumulated Other Comprehensive Income	-5,179
Net current period other comprehensive income	-1,501
Balance at September 28, 2013	3,932	5,433
Foreign currency
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance as of March 30, 2013		4,133
Other comprehensive income before reclassifications	332
Amounts reclassified from Accumulated Other Comprehensive Income	0
Net current period other comprehensive income	332
Balance at September 28, 2013	4,465	4,133
Defined benefit plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance as of March 30, 2013		-5,073
Net current period other comprehensive income	0
Balance at September 28, 2013	-5,073	-5,073
Net Unrealized Gain/loss on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance as of March 30, 2013		6,373
Other comprehensive income before reclassifications	3,346
Amounts reclassified from Accumulated Other Comprehensive Income	-5,179
Net current period other comprehensive income	-1,833
Balance at September 28, 2013	$4,540	$6,373

ACCUMULATED_OTHER_COMPREHENSIV2

ACCUMULATED OTHER COMPREHENSIVE INCOME (Details 2) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2013	Sep. 29, 2012	Sep. 28, 2013	Sep. 29, 2012
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Realized net gain on derivatives	($2,542)	($1,311)	($5,183)	($975)
Income tax effect	-4,340	-2,043	-2,965	-5,671
Net income	16,548	6,547	8,674	16,335
Net Unrealized Gain/loss on Derivatives | Amounts Reclassified from Other Comprehensive Income
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Realized net gain on derivatives			5,458
Income tax effect			-279
Net income			$5,179